Cyclerion Therapeutics
CYCN
90 hedge funds and large institutions have $237M invested in Cyclerion Therapeutics in 2019 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 35 increasing their positions, 17 reducing their positions, and 19 closing their positions.
106% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 17
6% more capital invested
Capital invested by funds: $223M → $237M (+$14M)
0.01% more ownership
Funds ownership: 3.55% → 3.56% (+0.01%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
13% less funds holding
Funds holding: 103 → 90 (-13)
63% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$7.18M |
| 2 |
UBS AM
Chicago,
Illinois
|
+$2.54M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.89M |
| 4 |
SPC
Slate Path Capital
New York
|
+$1.79M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BM
Bridger Management
New York
|
-$11.8M |
| 2 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
-$2.86M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$1.81M |
| 4 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$899K |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$737K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AAMU
101
Amundi Asset Management US
Boston,
Massachusetts
| – | -$5.4K | -25 | -93% |
|
102
Parallax Volatility Advisers
San Francisco,
California
| – | -$4K | -17 | Closed |
|
103
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$216 | -1 | Closed |
|
CYCN Hedge Fund Activity: Q3 2019 in Review
90 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Cyclerion Therapeutics (CYCN) for Q3 2019, worth a combined $237M — up 6.3% from $223M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of CYCN and 7 opened new positions — a net loss of 12 holders — while 17 trimmed existing stakes and 35 added.
The largest buyer was Camber Capital Management, adding an estimated $7.18M. The largest seller was Bridger Management, exiting entirely with an estimated $11.8M sold.
- 90 institutional investors held Cyclerion Therapeutics (CYCN) as of Q3 2019, down from 103 in Q2 2019.
- Funds reported $237M of Cyclerion Therapeutics stock for Q3 2019, up 6.3% quarter-over-quarter.
- 7 funds opened new Cyclerion Therapeutics positions in Q3 2019 and 19 closed out, a net change of -12 holders.
- The largest Cyclerion Therapeutics buyer in Q3 2019 was Camber Capital Management, an estimated $7.18M added.
- The largest Cyclerion Therapeutics seller in Q3 2019 was Bridger Management, an estimated $11.8M sold.
Based on aggregated 13F filings for Q3 2019.